Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Scientists Link Elevated Insulin To Increased Breast Cancer Risk
Elevated insulin levels in the blood appear to raise the risk of breast cancer in postmenopausal women, according to researchers at Albert Einstein College of Medicine of Yeshiva University. Their findings are published in the online version of the International Journal of Cancer.
generic viagra online
'Taking Up A Dialogue' With The Brain: Letter Decoding From Single-trial Brain Signals
Brain-computer interfaces "translate" what a person is thinking in words or actions. Researchers from Maastricht University in the Netherlands performed functional MRI brain scans on healthy participants, instructing them to "type" by performing mental tasks corresponding to different letters in the English alphabet. Researchers were able to use signals from the participants" brain activation patterns to decode information about the intended letter that a participant was thinking about, and to use this in a conversation with the experimenters without any spoken words. It is hoped that such technology can enable communication with "locked-in" patients or assessment of consciousness in non-responsive patients.
News of the day
Function Of Key Protein In Cancer Spread Described By LSUHSC Researchers
Research led by David Worthylake, PhD, Assistant Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, may help lay the groundwork for the development of a compound to prevent the spread of cancer. The research will be published in the May 29, 2009 issue of the Journal of Biological Chemistry.
Cardiovascular

Ventana's Promising New Anti-Obesity Patent

Ventana Biotech Inc ("Ventana")(PINK SHEETS:VNTA), a biotechnology company that is developing a appetite-suppressing chewing gum, released detailed information about its innovative Anti-Obesity Chewing Gum. The goal of Ventana"s Anti-Obesity Chewing Gum is to combat the growing global obesity epidemic while capturing a share of the multi-billion dollar market for anti-obesity drugs. How it works Ventana"s proprietary chewing gum contains an extract of hoodia gordonii and 2-hydroxyoleic acid. Hoodia gordonii is a leafless, cactus-like plant that grows naturally in Southern Africa that was historically used by native populations to suppress appetite when making long hunting trips in the Kalahari Desert. The plant has also been found to possess the ability to lower blood glucose levels, thereby also making it an attractive candidate for the treatment and prevention of diabetes. The active ingredients in the plant extracts are released into the patient"s blood stream, and trigger a hormonal response in the part of the brain (the hypothalamus) that tells the body it is "full", thereby suppressing the appetite of the obese patient. Because the plant extracts activate hormones that naturally exist in the body, there are no harmful side effects. The simple logic is that the Anti-Obesity Chewing Gum eliminates the feeling of "hunger", which in turn leads the patient to ingest less food, which in turn leads to weight loss. Obesity is a growing problem in developed nations, and is associated with increased mortality, Type 2 Diabetes, and heart disease. With Ventana"s proprietary Anti-Obesity Chewing Gum, users can safely control their appetites. Early indications show the Gum is able to reduce appetite by between 15 and 25 percent. Ventana continues to perfect this promising biotechnology and plans to eventually out-license it to Big Pharma companies. The royalty cash-flow from a successful anti-obesity drug is estimated at 1.5 - 1.7 billion Dollars. The outlook for anti-obesity treatments such as that of Ventana"s is promising, as the anti-obesity market continues to grow, while concurrently, the availability of successful patents is lacking. Morgan Stanley estimates the market for drugs combating Type 2 Diabetes (strongly correlated to obesity) to be in excess of $35 billion by 2012. Ventana Biotech Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009